Company Description
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.
It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFβ TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies.
In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884.
The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme.
The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011.
Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 1994 |
| IPO Date | Feb 4, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Garo Armen |
Contact Details
Address: 3 Forbes Road Lexington, Massachusetts 02421-7305 United States | |
| Phone | 781 674 4400 |
| Website | agenusbio.com |
Stock Details
| Ticker Symbol | AGEN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001098972 |
| CUSIP Number | 00847G804 |
| ISIN Number | US00847G8042 |
| Employer ID | 06-1562417 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer S. Buell Ph.D. | Director and President and Chief Executive Officer of MiNK Therapeutics |
| Dr. Garo H. Armen Ph.D. | Founder, Interim Chief Financial Officer, Principal Financial Officer, Chief Executive Officer and Executive Chairman |
| Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer |
| Austin Charette | Senior Director, Financial Reporting and Compliance and Principal Accounting Officer |
| Craig Winter | Chief Information Officer |
| Zack Armen | Vice President of Investor Relations and Corporate Development |
| Stefanie Perna-Nacar | Chief Communications and Government Relations Officer |
| Tracy Mazza Clemente | Chief People Officer |
| Dr. Todd Jude Yancey M.D. | Member of Advisory Board and Chief Strategic Advisor |
| Dr. Robin G. Taylor M.B.A., Ph.D. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 20, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 16, 2026 | 10-K | Annual Report |
| Mar 16, 2026 | 8-K | Current Report |
| Jan 23, 2026 | SCHEDULE 13D | Filing |
| Jan 16, 2026 | 8-K | Current Report |
| Jan 14, 2026 | 8-K | Current Report |
| Jan 8, 2026 | 8-K | Current Report |
| Dec 29, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |